Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study

Table 2 Comparison of blood glucose control, insulin dosage, and hypoglycemic events, n (%)/mean ± SD

Characteristic	Baseline	At 12 weeks	P value
HbA1c (%)	7.6 ± 1.1	7.4 ± 0.9	0.31
FBG (mmol/L)	10.4 ± 3.7	7.9 ± 2.5	0.02
Insulin dose, unit	53.3 ± 25.9	43.3 ± 18.1	0.03
Number of injections	3.95 ± 0.2	2.1 ± 0.3	< 0.01
Hypoglycemic events, n times per month			0.07
0	6 (28.6)	10 (47.6)
1-2	9 (42.9)	8 (38.1)
3-5	2 (9.5)	1 (4.8)
> 5	4 (19.0)	2 (9.5)

FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c.